Visits data shows demand at both your and your competitors facilities, with visibility to individual patient journeys and referrals.
Market Intelligence for Healthcare
Answers to your most important
strategy questions.
Our data-driven insights into healthcare demand, supply and yield enable healthcare stakeholders to develop evidence-based strategies.
OUR DATA FOUNDATIONS
The data you need to compete in healthcare's negative-sum game
The U.S. health economy is not a growing market in the traditional sense — the pool of commercially insured patients is shrinking every year — so any gain in market share for one stakeholder comes at the expense of another. Because the rules of a negative-sum game are immutable, the status quo is unsustainable and, therefore, a losing strategy. Competing effectively requires understanding your market through three lenses: demand, supply and yield.
DEMAND • VISITS
What care is happening?
Visits data shows demand at both your and your competitors facilities, with visibility to individual patient journeys and referrals.
SUPPLY • PROVIDERS
Who are the providers?
Provider data, including individual clinicians and healthcare organizations, presents an accurate view of supply in your market.
YIELD • RATES
How much does it cost?
Pricing data across health plans, settings of care and service lines equips stakeholders to deliver (or demand) value for money.
One comprehensive view of your market
OUR RESEARCH
Research on the health economy.
Open to everyone.
TRENDS REPORT • OCTOBER 2025
The U.S. health care system is at a crossroads. The choice for all health economy stakeholders is whether to implement radical and transformational change from the inside or whether to be subjected to such change by external forces.
-1.png?width=794&height=726&name=2025%20trends%20report%20cover%20(1)-1.png)
85.4%
After total knee arthroplasty (TKA) was removed from the IPO list in 2018, inpatient volumes declined by 17.9% from 2017 to 2018, with 2024 inpatient TKA volumes 85.4% below 2017.
744.6%
Surgical procedures are imperiled by novel drugs. Between 2018 and 2023, GLP-1 patients increased by 744.6%, while bariatric surgery volume was flat to declining.
8.5x
Inexplicable price variation contributes to high healthcare costs. Nationally, commercial negotiated rate for four distinct MS-DRGs vary by a factor of 8.5x, on average.
FROM OUR FOUNDER
"Every other industry in America uses data to develop evidence-based strategies, and only in healthcare do we rely on state hospital associations to report data from two years ago to decide what we're going to do in 2027."
Hal Andrews · President & CEO, Trilliant Health
The people behind the work
Meet the team...
Learn more about the team that builds the data, writes the research and works alongside clients to put it to use.
Hal AndrewsPresident and Chief Executive Officer
President and CEO since Trilliant Health's founding in June 2017, with more than 25 years' experience as an entrepreneur, investor and healthcare business leader.
Allison Oakes, Ph.D.VP, Chief Research Officer
Brings a comprehensive perspective to the complexities of the U.S. healthcare system. Published in leading medical journals. Background spans academia, government, health systems, and payers.
Matt O'NeillChief Data Officer and EVP Engineering, Machine Learning, Product
Strives to understand the data problems plaguing the healthcare industry, and how we can apply modern approaches in engineering and data science to solve them. Applies modern engineering and data science to healthcare's data problems.